Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Another Radeon RX 8000 GPU spotted in transit — Navi 44 XL GPU hints that RDNA 4 may mimic RDNA in product segmentation

The lifecycle of AMD's new (but still unannounced) GPU continues, and now we're seeing the low-end version move in shipping manifests.

Tom’s Hardware

S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points

Meta, Costco and Eli Lilly along with two others are trading near buy points coming out of a week marked by Nvidia earnings.

Investors Business Daily

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Oncology Stocks With Major Upside

With the rising prevalence of chronic diseases, increasing cell and gene therapies, and rising tech adoption in the biotech industry, the oncology market is booming. Amid this backdrop, investors could consider quality biotech stocks Pyxis Oncology (PYXS), Immatics (IMTX), and Jazz Pharmaceuticals (JAZZ), having significant upside potential. Continue reading.

StockNews.com

Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats

Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.

Investors Business Daily

‘A faulty contraceptive coil left me crippled in pain and forced to have a hysterectomy’

Mother tells Maya Oppenheim she was forced into having a hysterectomy which meant she ‘car crashed into menopause’ at the age of 45

The Independent UK

AMD reportedly delays B840 and B850 motherboards to early 2025 — only X870 and X870E will launch in September

AMD's budget-friendly B850 and B840 chipset motherboards will seemingly arrive in 2025, limiting AMD's September launch to its higher-end X-series chipsets.

Tom’s Hardware

Read news from The Economist, FT, and more,
with one subscription

Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell In December 2024?

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell in December 2024?

Investors Business Daily

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter

TG Therapeutics stock broke out Monday less than two weeks after the biotech company reported a surprise profit for the June quarter.

Investors Business Daily

Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 31%

Liquidia stock crashed Monday after the FDA delayed the final approval for its drug, Yutrepia, for patients with a pair of lung diseases.

Investors Business Daily

Biden-⁠Harris: Price Cuts on 10 Drugs to Save Medicare Beneficiaries $1.5 Billion

Historic Medicare drug price negotiations are said to lower costs on 10 best-selling drugs, saving Medicare beneficiaries $1.5 billion in out-of-pocket costs in the program's first year.

Kiplinger

IBD Stock Of The Day TG Therapeutics Flirts With Two Breakouts On Its Newfound Profitability

TG Therapeutics stock is the IBD Stock Of The Day as shares approach two potential entries on newfound profitability and booming sales.

Investors Business Daily

Big Pharma Push Back On First Medicare Drug Price Cuts

Major pharmaceutical companies lashed out following a landmark deal unveiled Thursday to cut the costs of 10 key medicines, with some saying the price-setting process was not transparent.

International Business Times

Big Pharma fought to keep prices high

Big Pharma exploited patent laws to stifle competition amid Medicare price negotiations, according to a new report

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Reeves should nail down UK AstraZeneca deal. A collapse would be embarrassing

Chancellor hopes to cut state aid for Speke vaccine plant to £40m. But pro-growth Treasury must not let project slip overseas

The Guardian - UK

Blow to AstraZeneca vaccine project as Reeves plans funding cuts

Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant

The Street

Analyst revises AbbVie stock price target on drug-sale estimates

This is what could happen next to AbbVie shares.

Investors Business Daily

Breakout Watch: Medical Stock In Buy Range, Notches All-Time High

DaVita stock launches a breakout to an all-time high as 44 A+ funds report a position in the kidney care leader.

Get all your
news in one place.

100’s of premium titles.
One news app.

Broadcasting & Cable

BranchLab Adds Errol Taylor as Advisor with Additional States Making Pharma Marketing More Difficult

Startup says it can provide consumer privacy and campaign effectiveness

The Street

Analysts reset targets for Eli Lilly shares

Here's what may happen next for the pharma giant's stock price.

The Guardian - UK

FTSE 100 chief executive pay reaches highest level on record

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

The Guardian - AU

‘Mind-boggling’: Victorian outreach workers decry double standard for lifesaving overdose drug naloxone

Untrained bystanders can legally administer the opioid-reversal treatment – but frontline staff workers face a legal risk if they do not first call triple zero

Investors Business Daily

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics

Avidity unveiled promising results for its DMD treatment on Friday and the top-notch biotech stock catapulted. RNA stock is highly rated.

Investors Business Daily

Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon

This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.

Kiplinger

Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter

Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Facebook

11,816 stories